Treating Patients With RCC Who Progress Following Adjuvant Therapy
The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.
Watch
NATALEE Trial Evaluates Ribociclib With ET in Early Breast Cancer
May 20th 2024Gabriel N. Hortabagyi, MD, FACP, provides an overview of the phase 3 NATALEE trial evaluating the combination of ribociclib with endocrine therapy as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer.
Watch
RCC: Informing Treatment Decisions with Clinical Trial Data
Experts on renal cell carcinoma discuss how clinical trial data inform treatment decisions, highlighting the negative results from PROSPER, CheckMate 914 Part A, and IMmotion010.
Watch
KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma
Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.
Watch
Dhakal on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM
May 17th 2024Binod Dhakal, MD, MS, discusses the basis of the FDA approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma that has been treated with at least 1 prior line of therapy and is refractory to lenalidomide.
Watch
In this segment, Dr. Shore will review the findings of several pivotal Phase 3 trials evaluating the efficacy of various treatments in metastatic hormone-sensitive prostate cancer patients, including the MAGNITUDE, PROpel, and TALAPRO-2 trials, among others.
Watch
ARASENS Trial- Darolutamide in mHSPC
May 15th 2024Dr. Shore will provide an overview of the Phase 3 ARASENS trial, which evaluated the efficacy of the androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel in hormone-sensitive prostate cancer patients. He will discuss the potential benefits of this combination in patients with high tumor burden mHSPC.
Watch
Treatment Intensification in Metastatic Prostate Cancer
May 15th 2024Dr. Shore will explore the evidence supporting treatment intensification through combining or sequencing therapies in metastatic prostate cancer. He will discuss the potential benefits and downsides of this approach, as well as which patients may benefit from an intensified treatment strategy.
Watch
In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.
Watch